Aiberry AI Mental Health Screening Platform
Development of the Aiberry AI Mental Health Screening Platform in a Diverse Population
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Study Manager
- Phone Number: (512) 827-9734
- Email: jocelyn.labrada@aiberry.com
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- University of Arizona
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20057
- Georgetown University
-
-
New York
-
New York, New York, United States, 10022
- Hapworth Research Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 13 to 79 years old
- English-speaking
Exclusion Criteria:
- Previous participant in the study, within the last three months
- Individuals unable to verbally respond to standardized questions
- Individuals unable to participate in a virtual visit as they do not have the right hardware (phone/laptop) or no internet connectivity
- Individuals unable to provide consent
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Interview & Depression Screening
|
Aiberry is a next-generation artificial intelligence (AI) company that leverages deep tech to screen for mental health and brain-related disorders.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prediction of depression score from a self-report instrument
Time Frame: Single assessment
|
Error when predicting depression severity (none, mild, moderate, severe) based on QIDS-SR-16.
|
Single assessment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Classification of moderate-severe depression
Time Frame: Single assessment
|
Accuracy, sensitivity, specificity, and positive and negative predictive value when classifying whether participants meet established cut-off criterion for suspected MDD (QIDS > 10)
|
Single assessment
|
|
Classification of moderate-severe anxiety
Time Frame: Single assessment
|
Accuracy, sensitivity, specificity, and positive and negative predictive value when classifying whether participants meet established cut-off criterion for suspected GAD (GAD-7 > 9)
|
Single assessment
|
|
Prediction of anxiety score from a self-report instrument
Time Frame: Single assessment
|
Error when predicting anxiety severity (none, mild, moderate, severe) based on GAD-7.
|
Single assessment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prediction of specific anxiety and depression symptoms
Time Frame: Single assessment
|
Error when predicting responses to individual items on the QIDS-SR or GAD-7.
|
Single assessment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Aiberry
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.